Showing 2811-2820 of 4109 results for "".
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- Dermatologists Seeing High Rates of Hair Loss after COVID-19https://practicaldermatology.com/news/dermatologists-seeing-high-rates-of-hair-loss-after-covid-19/2461034/When Paula Diaz contracted COVID, she expected to lose her sense of smell and taste but not her hair. “I spent six days in the hospital being treated for the virus and several weeks after I came home, my hair started falling out in clumps,” says Paula, who added that s
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- Survey: Consumers Interested in Medical Cannabis Products for Inflammatory Skin Disordershttps://practicaldermatology.com/news/survey-consumers-interested-in-medical-cannabis-products-for-inflammatory-skin-disorders/2461025/Patients with dermatologic conditions are open to trying medical cannabis products (MCPs) as potential treatments, according to a new study from George Washington University (GW) School of Medicine and Health Sciences (SMHS) and University of Maryland researchers. “MCPs, which are
- Dermatologist Tackles Misinformation Related to COVID-19 Vaccines and Injectable Fillers and Toxinxhttps://practicaldermatology.com/news/dermatologist-tackles-misinformation-related-to-covid-19-vaccines-and-injectable-fillers/2461022/With a recent article in the Wall Street Journal article suggesting that patients must choose between neurotoxin treatments or COVID-19 vaccines, dermatologists are scurrying to set the record straight. While there have been rare reports of non-life-threatening, transient reactions
- LEO Pharma's Adbry Approved for Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-approved-for-moderate-to-severe-ad/2461020/FDA has approved Adbry™ (tralokinumab-ldrm) from LEO Pharma Inc. for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry is the
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy